Cancer of unknown origin in gynaecologic oncology

Tumour of unknown primary (primum ignotum) is a metastatic disease that generally shows a poor response to treatment and prognosis. Although it exhibits a trend of decreasing incidence, the diagnostic processes are complicated. The available literature shows that 5–30% of metastases involve the ovary, but it remains unclear how often ovarian infiltration is found in tumours of unknown primary. The most common metastatic disease that affects the ovaries are malignant tumours of the gastrointestinal tract, breast, pancreas, and haematological malignancies. Usually, the first step to distinguish between a primary and a secondary tumour of the ovary is an ultrasound examination, where the ovarian metastases have some characteristic features. Here we report our experience with primum ignotum in a patient with simultaneous ovarian and bone marrow involvement.

Primum ignotum; Krukenberg tumour; Ovarian metastases

[1] Vikeså J, Møller AK, Kaczkowski B, Borup R, Winther O, Henao R, et al. Cancers of unknown primary origin (CUP) are characterised by chromosomal instability (CIN) compared to metastasis of known origin. BMC Cancer. 2015; 15: 151.

[2] Fizazi K, Greco FA, Pavlidis N, Daugaard G, Oien K, Pentheroudakis G, et al; ESMO Guidelines Committee. Cancers of the unknown primary site: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2015; 26: v133–8.

[3] Sugarbaker PH. Peritoneal carcinomatosis of an unknown primary site may be an undiagnosed appendiceal adenocarcinoma. A case series. International Journal of Surgery Case Reports. 2019; 63: 65–68.

[4] Laprovitera N, Riefolo M, Ambrosini E, Klec C, Pichler M, Ferracin M. Cancer of unknown primary: challenges and progress in clinical management. Cancers. 2021; 13: 451.

[5] Safri LS, Md Noh MSF, Hariz Ramli AR, Md Pauzi SH, Md Idris MA, Harunarashid H. A case of metastatic adenocarcinoma from an unknown primary involving the aortic bifurcation. Journal of Vascular Surgery Cases, Innovations and Techniques. 2018; 4: 160–162.

[6] Golfinopoulos V, Pentheroudakis G, Salanti G, Nearchou AD, Ioannidis JP, Pavlidis N. Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: a multiple-treatments meta-analysis. Cancer Treatment Reviews. 2009; 35: 570–3.

[7] Testa AC, Ferrandina G, Timmerman D, Savelli L, Ludovisi M, Van Holsbeke C, et al. Imaging in gynaecological disease (1): ultrasound features of metastases in the ovaries differ depending on the origin of the primary tumour. Ultrasound in Obstetrics & Gynecology. 2007; 29: 505–11.

[8] Greco FA, Lennington WJ, Spigel DR, Hainsworth JD. Molecular profiling diagnosis in unknown primary cancer: accuracy and ability to complement standard pathology. Journal of the National Cancer Institute. 2013; 105: 782–90.

[9] Shah B, Tang W, Karn S. An up-to-date understanding of the “krukenberg tumor” mechanism. Advances in Reproductive Sciences. 2016; 4: 31–36.